Alphamab Oncology (9966.HK)

HKD 7.85

(21.52%)

Total Debt Summary of Alphamab Oncology

  • Alphamab Oncology's latest annual total debt in 2023 was 257.08 Million CNY , down -25.57% from previous year.
  • Alphamab Oncology's latest quarterly total debt in 2024 Q2 was 320 Million CNY , down 0.0% from previous quarter.
  • Alphamab Oncology reported annual total debt of 345.39 Million CNY in 2022, down -45.8% from previous year.
  • Alphamab Oncology reported annual total debt of 637.27 Million CNY in 2021, up 186.02% from previous year.
  • Alphamab Oncology reported quarterly total debt of 257.08 Million CNY for 2023 Q4, down 0.0% from previous quarter.
  • Alphamab Oncology reported quarterly total debt of 257.08 Million CNY for 2023 FY, down -25.57% from previous quarter.

Annual Total Debt Chart of Alphamab Oncology (2023 - 2017)

Historical Annual Total Debt of Alphamab Oncology (2023 - 2017)

Year Total Debt Total Debt Growth
2023 257.08 Million CNY -25.57%
2022 345.39 Million CNY -45.8%
2021 637.27 Million CNY 186.02%
2020 222.8 Million CNY -12.0%
2019 253.17 Million CNY 128.05%
2018 111.02 Million CNY 5428.88%
2017 2 Million CNY 0.0%

Peer Total Debt Comparison of Alphamab Oncology

Name Total Debt Total Debt Difference
Uni-Bio Science Group Limited 52.86 Million HKD -386.277%
CK Life Sciences Int'l., (Holdings) Inc. 5.93 Billion HKD 95.666%